HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome

@article{Chen2010HLAmismatchedHS,
  title={HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome},
  author={Y H Chen and Kai Yan Liu and Lanping Xu and Huan Chen and Dai Hong Liu and Xiaohui Zhang and H Shi and Wei Han and Yu Wang and Ting Zhao and Jing-bo Wang and X-j Huang},
  journal={Bone Marrow Transplantation},
  year={2010},
  volume={45},
  pages={1333-1339}
}
Allogeneic hematopoietic SCT (HSCT) is currently the only curative treatment for myelodysplastic syndrome (MDS). However, many patients cannot find an HLA-matched donor. We have developed a new protocol for HLA-mismatched (including haploidentical) HSCT using G-CSF-primed BM plus G-CSF-mobilized PBSCs without in vitro T-cell depletion. A total of 36 patients diagnosed with high-risk MDS (RAEB (refractory anemia with excess blasts) or RAEBt (RAEB in transformation)) underwent transplantation… CONTINUE READING
10 Citations
29 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

siveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions

  • J Sierra, WS Pérez, C Rozman, E Carreras, JP Klein, JD Rizzo
  • Transpl Immunol
  • 2007

Similar Papers

Loading similar papers…